1
Return

Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy

delete2025-02-01
delete0
PRE
AI
A
Alexandra Butters
C
Clare Arnott
J
Joanna Sweeting
B
Brian Claggett
A
Anna Cuomo
D
Dominic J. Abrams
E
Euan A. Ashley
S
Sharlene M. Day
A
Adam Helms
R
Rachel Lampert
K
Kimberly Y. Lin
M
Michelle Michels
E
Erin M. Miller
I
Iacopo Olivotto
A
Anjali Owens
V
Victoria N. Parikh
A
Alexandre C. Pereira
J
Joseph W. Rossano
T
Thomas D. Ryan
S
Sara Saberi
J
John C. Stendahl
J
James S. Ware
J
J. Atherton
C
Christopher Semsarian
N
Neal K. Lakdawala
C
Carolyn Y. Ho
J
Jodie Ingles *
DOI:10.1161/CIRCGEN.124.004641delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
BACKGROUND:Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are unclear. We aimed to investigate sex-related differences in clinical and genetic factors affecting adverse outcomes in the Sarcomeric Human Cardiomyopathy Registry. METHODS:Cox proportional hazard models were fit with a sex interaction term to determine if significant sex differences existed in the association between risk factors and outcomes. Models were fit separately for females and males to find the sex-specific hazard ratio (HR). RESULTS:After a mean follow-up of 6.4 years, females had a higher risk of heart failure (HR, 1.51 [95% CI, 1.21-1.88]; P=0.0003) but a lower risk of atrial fibrillation (HR, 0.74 [95% CI, 0.59-0.93]; P<0.0001) and ventricular arrhythmia (HR, 0.60 [95% CI, 0.38-0.94]; P=0.027) than males. No sex difference was observed for death (P=0.84). Sarcomere-positive males had higher heart failure (HR, 1.34 [95% CI, 1.06-1.69]) and death risks (HR, 1.48 [95% CI, 1.08-2.04]) not seen in females (HR, 0.85 [95% CI, 0.66-1.08] versus HR, 0.86 [95% CI, 0.71-1.21]). MYBPC3 variants lowered heart failure risk in females (HR, 0.56 [95% CI, 0.41-0.77]) but not in males (HR, 1.29 [95% CI, 0.99-1.67]). A sex difference appeared in moderate (4% to <6%) versus low risk (<4%) European Society of Cardiology hypertrophic cardiomyopathy risk score, with females at moderate risk more prone to ventricular arrhythmia (HR, 3.57 [95% CI, 1.70-7.49]), unobserved in males (HR, 1.13 [95% CI, 0.63-2.03]). CONCLUSIONS:We found that clinical and genetic factors contributing to adverse outcomes in hypertrophic cardiomyopathy affect females and males differently. Thus, research to inform sex-specific management of hypertrophic cardiomyopathy could improve outcomes for both sexes.
Keywords:
cardiomyopathy, hypertrophic
female
heart failure
male
sex

Journal

Circulation-Genomic and Precision Medicine cover
Circulation-Genomic and Precision Medicine
IF:
5.5
Papers:
684
Citations:
2.4K

Organization

R
Royal Prince Alfred Hospital
Scholars:
3.3K
Papers: 2.6K
Citations: 5.5K
G
Garvan Institute of Medical Research
Scholars:
3.2K
Papers: 2.3K
Citations: 7.1K
H
Harvard University
Scholars:
26.2W
Papers: 21.9W
Citations: 28.7W
U
University of Sydney
Scholars:
6.5W
Papers: 6.2W
Citations: 90
H
harvard university medical affiliates
Scholars:
5.7W
Papers: 4.5W
Citations: 36
S
Stanford University
Scholars:
9.6W
Papers: 8.2W
Citations: 17.0W
N
NSW Health
Scholars:
1.9W
Papers: 1.5W
Citations: 12
U
University of Michigan
Scholars:
6.4W
Papers: 5.3W
Citations: 124
H
Harvard Medical School
Scholars:
6.5W
Papers: 4.8W
Citations: 91
Cited Papers

Cited Papers

Citing Papers

Citing Papers